Table 2 Factor influencing neurological outcomes
Factor | Parameter | p value |
|---|---|---|
Type of treatment | PSD 3 (16.7%), PS 2 (13.3%), Rad 10 (18.8%) | 0.9642 |
Male vs. female | 9/61 (14.8%) vs. 6/27 (22.2%) | 0.3902 |
Age (years), mean | 39–85, 64.4 ± 12.6 | 0.9956 |
The level of the spine that exhibited the greatest tumor-related spinal cord compression | C1-T2 level 2 (11.8%), T3-L1 level 8 (25.0%), L2-S1 level 5 (12.8%) | 0.3539 |
No. of affected vertebral body, mean | 1–8, 3.4 ± 2.3 | 0.5415 |
Primary site | Lung 7, kidney 3, colon 1, unknown 3, others 1 | 0.6713 |
No. of VAS 0 | 2 (13.3%) | 0.2717 |
Transverse location | A 6 (13.3%), AP 3 (15.8%), AF 5 (23.8%), APF 3 (60%) | 0.9316 |
ESCC scale | 1b 5 (11.3%), 1c 6 (20.7%), 2 3 (25%), 3 1 (33.3%) | 0.1325 |
Spinal instability neoplastic score | 10.5 ± 8.6 (vs. 9.5 ± 5.4) | 0.2287 |
Additional adjuvant therapy | No 6/26 (23.1%) | 0.3299 |
Survival period (months), mean | 1.5–20, 7.7 ± 6.0 | 0.4296 |
Pre-treatment Barthel index, mean | 40–100, 89.3 ± 22.4 | 0.0666 |